The US Food and Drug Administration (FDA) recently issued final guidance (June 2021) for Biologics industry executives to help define modifications to existing products and update submission procedures.  The primary focus of the guidance is to help biologics industry employees responsible for reporting understand which type of risk category is appropriate for updated variations in … Continue reading FDA Publishes Updated Biologics Guidance